A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of WJ47156 Monotherapy and in Combination With Other Anti-Tumor Therapies in Patients With Advanced Malignant Solid Tumors
Latest Information Update: 10 Jul 2026
At a glance
- Drugs WJ 47156 (Primary) ; Bevacizumab; Toripalimab
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Shanghai Junshi Biosciences
Most Recent Events
- 07 Jul 2026 Planned primary completion date changed from 15 May 2026 to 15 Dec 2026.
- 07 Jul 2026 Status changed from recruiting to active, no longer recruiting.
- 31 Oct 2024 Status changed from not yet recruiting to recruiting.